Literature DB >> 32949294

Relationship Between Severity of T Cell Lymphopenia and Immune Dysregulation in Patients with DiGeorge Syndrome (22q11.2 Deletions and/or Related TBX1 Mutations): a USIDNET Study.

Deepti R Deshpande1, Yesim Y Demirdag2, Rebecca A Marsh3, Kathleen E Sullivan4, Jordan S Orange5.   

Abstract

PURPOSE: DiGeorge syndrome has substantial heterogeneity with variable immune deficiency and dysregulation. Implicated immunopathology includes reduced thymic output and increased peripheral homeostatic proliferation with Th2 skewing and expansion of self-reactive cells. We hypothesized that T cell lymphopenia severity will be associated with higher odds of autoimmunity and/or asthma.
METHODS: Using the US Immunodeficiency Network registry, we identified patients with 22q11.2 deletion (and/or TBX1). Initial absolute CD3+ T cell values were stratified: normal, 50-99% and below 50% of the lower limit of age-adjusted normal values. Patients with and without reported autoimmunity and asthma were compared using chi-square tests and multivariate logistic regression.
RESULTS: Among 415 patients, autoimmunity was reported in 17 (4.1%), and asthma was reported in 28 (6.7%). Compared with those with no reported autoimmunity, patients with reported autoimmunity more frequently had low CD19+ B cells [3.3% (12/364) vs 28.6% (4/14); p = 0.002] and low IgG [6.2% (20/321) vs 29.4% (5/17); p = 0.005] levels. There were no statistically significant differences in other immune characteristics among those with and without reported asthma. Patients with absolute CD3 levels below 50% of age-adjusted normal values had higher odds of reported autoimmunity (n = 319, OR = 7.56, 95% CI = 1.58-36.17, p = 0.01) and reported asthma (n = 319, OR = 4.5, 95% CI = 1.06-18.93, p = 0.04) as compared with those with normal CD3 values, adjusted for age and low IgG.
CONCLUSIONS: Absolute CD3+ T cell counts below 50% of age-adjusted normal values may be associated with higher odds of autoimmunity and/or asthma in patients with DiGeorge syndrome and be potentially useful to identify higher-risk patients.

Entities:  

Keywords:  22q11.2; DiGeorge syndrome; asthma; autoimmunity; infections; lymphopenia

Mesh:

Substances:

Year:  2020        PMID: 32949294     DOI: 10.1007/s10875-020-00854-y

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  13 in total

1.  Paediatric reference values for the peripheral T cell compartment.

Authors:  E J H Schatorjé; E F A Gemen; G J A Driessen; J Leuvenink; R W N M van Hout; E de Vries
Journal:  Scand J Immunol       Date:  2012-04       Impact factor: 3.487

Review 2.  Chromosome 22q11.2 deletion syndrome and DiGeorge syndrome.

Authors:  Kathleen E Sullivan
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

Review 3.  The immune deficiency of chromosome 22q11.2 deletion syndrome.

Authors:  Megan Morsheimer; Terri F Brown Whitehorn; Jennifer Heimall; Kathleen E Sullivan
Journal:  Am J Med Genet A       Date:  2017-06-19       Impact factor: 2.802

4.  Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  A F Jawad; D M McDonald-Mcginn; E Zackai; K E Sullivan
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

5.  Reduced frequency of peripheral CD4+CD45RA+CD31+ cells and autoimmunity phenomena in patients affected by Del22q11 syndrome.

Authors:  Silvia Ricci; Marzio Masini; Claudia Valleriani; Arianna Casini; Martina Cortimiglia; Laura Grisotto; Clementina Canessa; Giuseppe Indolfi; Francesca Lippi; Chiara Azzari
Journal:  Clin Immunol       Date:  2017-12-29       Impact factor: 3.969

6.  Clinical and immunological features in a cohort of patients with partial DiGeorge syndrome followed at a single center.

Authors:  Giuliana Giardino; Nesrine Radwan; Patra Koletsi; Deborah M Morrogh; Stuart Adams; Winnie Ip; Austen Worth; Alison Jones; Imke Meyer-Parsonson; H Bobby Gaspar; Kimberly Gilmour; E Graham Davies; Fani Ladomenou
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

7.  CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia.

Authors:  Kathleen E Sullivan; Donna McDonald-McGinn; Elaine H Zackai
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 8.  Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome.

Authors:  Blaine Crowley; Melanie Ruffner; Donna M McDonald McGinn; Kathleen E Sullivan
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

9.  Thymic Epithelium Abnormalities in DiGeorge and Down Syndrome Patients Contribute to Dysregulation in T Cell Development.

Authors:  Genni Enza Marcovecchio; Ileana Bortolomai; Francesca Ferrua; Elena Fontana; Luisa Imberti; Erika Conforti; Donato Amodio; Sonia Bergante; Giulia Macchiarulo; Veronica D'Oria; Francesca Conti; Silvia Di Cesare; Georgia Fousteri; Adriano Carotti; Alessandro Giamberti; Pietro Luigi Poliani; Luigi D Notarangelo; Caterina Cancrini; Anna Villa; Marita Bosticardo
Journal:  Front Immunol       Date:  2019-03-15       Impact factor: 7.561

10.  Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  M Pierdominici; F Mazzetta; E Caprini; M Marziali; M C Digilio; B Marino; A Aiuti; F Amati; G Russo; G Novelli; F Pandolfi; G Luzi; A Giovannetti
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

View more
  2 in total

Review 1.  Thymic origins of autoimmunity-lessons from inborn errors of immunity.

Authors:  Rosa Bacchetta; Kenneth Weinberg
Journal:  Semin Immunopathol       Date:  2021-02-02       Impact factor: 9.623

2.  Long-Term Follow-Up of Newborns with 22q11 Deletion Syndrome and Low TRECs.

Authors:  Jenny Lingman Framme; Christina Lundqvist; Anna-Carin Lundell; Pauline A van Schouwenburg; Andri L Lemarquis; Karolina Thörn; Susanne Lindgren; Judith Gudmundsdottir; Vanja Lundberg; Sofie Degerman; Rolf H Zetterström; Stephan Borte; Lennart Hammarström; Esbjörn Telemo; Magnus Hultdin; Mirjam van der Burg; Anders Fasth; Sólveig Oskarsdóttir; Olov Ekwall
Journal:  J Clin Immunol       Date:  2022-01-26       Impact factor: 8.542

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.